Manufacturing review of the cangaroo envelope device history record for the reported lot shows that all packaged and labeled units were quality released to distribution on 01/24/2020 having met all internal qc acceptance requirements.All sterilization processing records and bioburden testing indicate a successful sterilization cycle and passing results of product lal and sterility samples allowing the subassembly lot to be released for further packaging and labeling having met all criteria for release.There were no non-conformances during manufacturing or sterilization potentially impacting the final acceptance of this manufacturing lot.In lieu of a request for the oem supplier dhr review, it is noted that aziyo processes the non-sterile envelope materials including cutting, suturing, packaging and sterilizing the product.It should be noted that per the instructions for use (ifu - art-20662) provided with the finished cangaroo envelope device, infection is listed as a potential complication associated with the procedure and device.Although the exact cause of the reported infection cannot be conclusively determined, infection is a known complication associated with the use of a cangaroo envelope and a surgical implant procedure.Should aziyo receive any additional details related to this event, a supplemental report will be filed.
|
It was reported by an aziyo sales representative on 10/15/2020 that a male patient had previously been implanted with a biv icd (model #: unknown, serial #: unknown) using a cangaroo envelope (model #: cmcv-009-xlg; lot # m20a1038).Patient later returned with pus in the pocket, redness of pocket and diagnosed with a local pocket infection.The patient was treated with 5 days of antibiotics and the biv icd device was explanted and replaced with a subq device.Sales representative learned of event 2 - 3 weeks after occurrence, dates of implant and explant unknown.Should any additional details be received, a follow-up report will be filed.
|